METiS Pharmaceuticals, an AI-driven drug company based in Hangzhou, is planning an IPO in Hong Kong to raise up to US$200 million.

The company is working with advisors to arrange the offering, which could take place by the end of 2025.

Founded in 2020, METiS has raised around US$300 million, including a US$100 million Series C round in June 2024 led by CICC Capital.

Other investors in the latest round include China Taiping Insurance Holdings and HongShan, formerly Sequoia China.

METiS also operates offices in Beijing, Shanghai, and Cambridge, Massachusetts, and has not commented publicly on the IPO.

🔗 Source: Bloomberg

🧠 Food for thought

1️⃣ AI pharmaceutical sector attracts massive capital despite profitability challenges

METiS Pharmaceuticals’ potential $200 million IPO follows a pattern of substantial investment in AI-driven drug discovery companies despite uncertain financial performance.

The company has already secured $300 million in funding since its 2020 founding, including a recent $100 million Series C round led by CICC Capital 1.

This mirrors other AI pharmaceutical companies like Tempus AI, which is targeting a $400 million IPO despite reporting significant net losses of $214 million in 2023 2.

The investment enthusiasm persists because AI drug discovery promises to drastically reduce the traditional decade-long, billion-dollar drug development process, as evidenced by companies like Exscientia which uses AI to significantly cut discovery timelines 3.

Investors appear willing to accept lengthy paths to profitability, focusing instead on the revolutionary potential of combining AI with pharmaceutical development, as demonstrated by the more than 450 life sciences companies now leveraging AI for drug discovery 4.

2️⃣ China’s AI pharmaceutical market shows explosive growth potential

METiS’s rapid fundraising and IPO plans reflect the broader acceleration of China’s AI pharmaceutical sector, which is projected to grow at a compound annual growth rate of 56.8% from 2020 to 2025 5.

The company benefits from favorable government policies in China that actively support AI-driven biotech innovation, creating a conducive environment for rapid expansion 1.